GeneDx Holdings (NASDAQ: WGS) saw its stock rise over 8% following a strong second-quarter earnings report that revealed nearly $103 million in revenue, a 49% year-over-year increase, driven by a 69% surge in exome and genome testing sales. This performance stood in stark contrast to the S&P 500’s modest 0.3% decline.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
